In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, DiaMedica Therapeutics Inc’s stock clocked out at $5.37, up 1.32% from its previous closing price of $5.3. In other words, the price has increased by $1.32 from its previous closing price. On the day, 0.6 million shares were traded. DMAC stock price reached its highest trading level at $5.763 during the session, while it also had its lowest trading level at $5.1501.
Ratios:
To gain a deeper understanding of DMAC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.55 and its Current Ratio is at 7.55. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
Oppenheimer Upgraded its Perform to Outperform on June 22, 2023, while the target price for the stock was maintained at $7.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 25 ’25 when STAHLBERG JAN bought 338,265 shares for $6.00 per share. The transaction valued at 2,029,252 led to the insider holds 7,654,045 shares of the business.
STAHLBERG JAN bought 293,601 shares of DMAC for $1,734,918 on Aug 13 ’25. The 10% Owner now owns 7,058,066 shares after completing the transaction at $5.91 per share. On Aug 14 ’25, another insider, STAHLBERG JAN, who serves as the 10% Owner of the company, bought 70,414 shares for $5.99 each. As a result, the insider paid 421,921 and bolstered with 7,128,480 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DMAC now has a Market Capitalization of 277569376 and an Enterprise Value of 247823456.
Stock Price History:
The Beta on a monthly basis for DMAC is 1.38, which has changed by 0.33250618 over the last 52 weeks, in comparison to a change of 0.20221436 over the same period for the S&P500. Over the past 52 weeks, DMAC has reached a high of $6.82, while it has fallen to a 52-week low of $3.19. The 50-Day Moving Average of the stock is 12.84%, while the 200-Day Moving Average is calculated to be 10.74%.
Shares Statistics:
It appears that DMAC traded 339.68K shares on average per day over the past three months and 317200 shares per day over the past ten days. A total of 43.07M shares are outstanding, with a floating share count of 22.77M. Insiders hold about 55.94% of the company’s shares, while institutions hold 17.06% stake in the company. Shares short for DMAC as of 1755216000 were 3831402 with a Short Ratio of 11.28, compared to 1752537600 on 2413284. Therefore, it implies a Short% of Shares Outstanding of 3831402 and a Short% of Float of 10.7.
Earnings Estimates
A detailed examination of DiaMedica Therapeutics Inc (DMAC) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.15 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.65 and -$0.72 for the fiscal current year, implying an average EPS of -$0.68. EPS for the following year is -$0.74, with 3.0 analysts recommending between -$0.63 and -$0.84.
